News - Pharmaceuticals
Precision prescribing to combat Australia’s expected surge in mental illness

Pharma News: COVID-19 social isolation, familial and community disconnection, shock, job loss and health fears create the perfect storm for a person who is vulnerable to mental illness.
1 million Australians suffer from depression in any one year.
New modelling by the University of Sydney’s Brain and Mind Centre confirms our fears, that the COVID-19 pandemic may see more deaths by suicide than by the virus itself. Predictions estimate a 25% increase to suicide rates and even higher rates for younger Australians.
In a recent submission to the Australian Department of Health, myDNA outlined how precision prescribing and pharmacogenomics could be a a new, and vitally important, dimension in the fight against such a shocking tidal wave of suicide and depression.
Specialists or GPs employ a level of guess work when recommending which anti-depressant treatment will work the first time. Studies show, 50% of the time, it will take three or more attempts of prescribing yet another medicine before the right treatment finally settles for that patient. This is because, when it comes to mental health, our genes run interference with how we react to medication.
Australian-based company, myDNA, has researched and developed a new way of determining the best antidepressant treatment for patients suffering from mental health disorders. This is achieved through a genetic test that can reveal a person’s ability to processes and metabolise certain medications. Known as Pharmacogenomics, this test is converted into vital knowledge for a doctor, who can then be certain that the medication they prescribe is personalised and accurate – the first time.
This type of test is now used by Australia’s leading pathology services providing such tests for doctors and support services in pharmacies across the country.
Amid fears that this pandemic could spawn a ‘generational mental health crisis,’ pharmacogenomics and with it, precision prescribing, have an important role to play in protecting those Australians struggling with mental illness.
Leadership & Management
David Henderson appointed Takeda Oceania Country Head
David Henderson has been appointed Country Head for Takeda Oceania, succeeding Dave Pearce, as the pharmaceutical company continues to reshape […]
MoreNews - Pharmaceuticals
GBMA puts medicine shortages on the table as strategic agreement talks begin
As the Generic and Biosimilar Medicines Association (GBMA) begins negotiations with government on the next strategic agreement, it has unveiled […]
MoreNews - MedTech & Diagnostics
Australia sets a new course for prostate cancer detection
Australia has become one of the first countries in the world to adopt a modern, evidence-based framework for the early […]
MoreNews - Pharmaceuticals
IVF success rates climb as ART sector faces major accreditation overhaul
Australians undergoing in vitro fertilisation (IVF) are now more likely to take home a baby than they were five years […]
More